CN107333750A - Blood cell stabilizer when a kind of long - Google Patents

Abstract

The invention provides a long-term blood cell stabilizer, the stabilizer is composed of the following components: disodium cromoglycate 20-40 μmol/L, poloxamer 0.12-0.16 mg/L, β-cycloglucose Ethanol 120~140 μmol/L, ecodoine 10~12 μmol/L, triflusal 20~25 μmol/L, potassium dichromate 0.07%, trehalose 80~200 μmol/L, the potassium dichromate is the mass percent concentration. The blood cell stabilizer obtained in the present invention can very effectively stabilize blood cells in blood and prevent platelet aggregation, and can provide blood cells with a stabilizing effect for at least 120 hours. Compared with existing products, the stabilization time is extended by at least 48 hours .

Description

A long-term blood cell stabilizer

technical field

The invention belongs to the technical field of cells, and in particular relates to a long-term blood cell stabilizer.

Background technique

In related blood research and clinical research, the stability of blood cells is very important. Generally speaking, after whole blood is collected, common blood anticoagulants can only provide blood stabilization within 6 hours. As an alternative reagent, formaldehyde fixative (such as Kryofix) is also often used, but formaldehyde is toxic and easy to volatilize, and there are certain quality control difficulties and safety hazards.

In recent years, some new blood cell stabilizers have appeared one after another, which mainly stabilize the cell membrane through β-cyclodextrin, disodium cromoglycate and potassium dichromate. Glycosides to further provide blood stabilizing effects. However, the stability time provided by existing stabilizers is still very limited, and the most common time known so far is only 72 hours.

In major disaster medical assistance or medical assistance in remote areas, the 72-hour stabilization period is often not enough. In addition, in some blood tests that take a long time, due to the need for consistent blood sources, it is difficult for ordinary stabilizers to provide such a long stabilization time, making it difficult to carry out corresponding tests.

Contents of the invention

Aiming at the shortcoming of the short stable period provided by the blood cell stabilizer in the prior art, one of the objects of the present invention is to provide a long-term blood cell stabilizer, the stabilizer is composed of the following components:

Disodium cromolyn 20~40 μmol/L

Poloxamer 0.12~0.16 mg/L

β-cyclodextrin 120~140 μmol/L

Ecodoine 10~12 μmol/L

Triflusal 20~25 μmol/L

Potassium dichromate 0.07%

Trehalose 80~200 μmol/L

The potassium dichromate is a mass percent concentration.

As a preferred version, the stabilizer consists of the following components:

Disodium cromolyn 25 μmol/L

Poloxamer 0.13 mg/L

β-cyclodextrin 125 μmol/L

Ecodoine 11.5 μmol/L

Triflusal 23 μmol/L

Potassium dichromate 0.07%

Trehalose 160 μmol/L

The potassium dichromate is a mass percent concentration.

Another object of the present invention is to provide the application of the above-mentioned blood cell stabilizer in stabilizing blood.

Compared with the prior art, the present invention has the following advantages:

The blood cell stabilizer obtained in the present invention can very effectively stabilize blood cells in blood and prevent platelet aggregation, and can provide blood cells with a stabilizing effect for at least 120 hours. Compared with existing products, the stabilization time is extended by at least 48 hours .

detailed description

The present invention is described in detail by the following examples, it is necessary to point out that the following examples are only used to further illustrate the present invention, and can not be interpreted as limiting the scope of the present invention, those skilled in the art according to the content of the above invention Some non-essential improvements and adjustments made still belong to the protection scope of the present invention.

Example 1

According to the following concentrations, weigh the raw materials of each component, dissolve them in sterile deionized water, and make to volume.

Disodium cromolyn 25 μmol/L

Poloxamer 0.13 mg/L

β-cyclodextrin 125 μmol/L

Ecodoine 11.5 μmol/L

Triflusal 23 μmol/L

Potassium dichromate 0.07%

Trehalose 160 μmol/L

The potassium dichromate is a mass percent concentration.

Example 2

According to the following concentrations, weigh the raw materials of each component, dissolve them in sterile deionized water, and make to volume.

Disodium cromolyn 20μmol/L

Poloxamer 0.12 mg/L

β-cyclodextrin 120μmol/L

Ecodoine 10μmol/L

Triflusal 20 μmol/L

Potassium dichromate 0.07%

Trehalose 80 μmol/L

The potassium dichromate is a mass percent concentration.

Example 3

According to the following concentrations, weigh the raw materials of each component, dissolve them in sterile deionized water, and make to volume.

Disodium cromolyn 40 μmol/L

Poloxamer 0.16 mg/L

β-cyclodextrin 140 μmol/L

Ecodoine 12 μmol/L

Triflusal 25μmol/L

Potassium dichromate 0.07%

Trehalose 200 μmol/L

The potassium dichromate is a mass percent concentration.

Comparative example 1

Except that the concentration of disodium cromoglycate was 18 μmol/L, and the concentration of ecodoine was 15 μmol/L, the others were consistent with Example 1.

Comparative example 2

Except that trehalose was replaced by PEG1000 at a concentration of 1.25 mmol/L, and the concentration of ectoine was 15 μmol/L, the rest was the same as that of Example 1.

Comparative example 3

The stabilizer obtained in Example 6 in Chinese Patent 201410784318.3.

Comparative example

The stabilizer obtained in Example 1 in Chinese Patent 201410534999.8.

The stabilizer obtained in Examples 1-3 was added to the whole blood sample, and after standard storage for 120 hours, it was taken out and observed with the naked eye. The color of the whole blood sample was consistent with that before storage, showing red, and the blood sample had no coagulation phenomenon. The stabilizer obtained in Comparative Examples 1-4 was added to the whole blood sample, and after standard storage for 120 hours, it was taken out and observed with the naked eye. The whole blood sample coagulated to varying degrees, and the color became light and light red. It shows that using the blood cell stabilizer of the present invention, after 120 hours of preservation, the cells in the blood are still stable.

Claims (3)

1. A long-term blood cell stabilizer, characterized in that, the stabilizer is made up of the following components: Disodium cromolyn 20~40 μmol/L Poloxamer 0.12~0.16 mg/L β-cyclodextrin 120~140 μmol/L Ecodoine 10~12 μmol/L Triflusal 20~25 μmol/L Potassium dichromate 0.07% Trehalose 80~200 μmol/L The potassium dichromate is a mass percent concentration. 2. stabilizer according to claim 1, is characterized in that, described stabilizer, is made up of following components: Disodium cromolyn 25 μmol/L Poloxamer 0.13 mg/L β-cyclodextrin 125 μmol/L Ecodoine 11.5 μmol/L Triflusal 23 μmol/L Potassium dichromate 0.07% Trehalose 160 μmol/L The potassium dichromate is a mass percent concentration. 3. The application of the stabilizing agent according to claim 1 or 2 in stabilizing blood.